{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-23-000018","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.819190+00:00","generated_at":"2026-06-16T02:33:52.943056+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexicon reports Q1 net loss of $31.9M; PDUFA for sotagliflozin on track for May 27","bullets":["Q1 2023 net loss $31.9M ($0.17/share), compared to $23.5M ($0.16/share) in Q1 2022.","Cash and investments $105.9M at Mar 31, down from $138.4M at Dec 31, 2022.","NDA for heart failure drug sotagliflozin has May 27 PDUFA action date; company prepared for prompt US launch.","R&D spending fell to $12.1M; SG&A rose to $19.1M on commercial launch preparations.","LX9211 for neuropathic pain advancing; FDA feedback on late-stage development expected in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-23-000018","json":"https://secwatch.observer/filing/0001062822-23-000018.json","markdown":"https://secwatch.observer/filing/0001062822-23-000018.md","text":"https://secwatch.observer/filing/0001062822-23-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000018/0001062822-23-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000018/lxrx-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:33:52.943056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d73a006b2b5f73a86a6a9c150d8deb312b776fac","claim":"LEXICON PHARMACEUTICALS, INC. reported the three months ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $31.9 million, or $0.17 per share, EPS $0.17 per share.","evidence_excerpt":"Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000018/0001062822-23-000018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"Net loss for the first quarter of 2023 was $31.9 million, or $0.17 per share"},{"label":"EPS","value":"$0.17 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}